Time New York: Tue 19 Jun 06:11 am  |  Save 15% on H&R Block Online


Strength Seen in FibroGen (FGEN): Stock Soars 48.2%


FibroGen, Inc. FGEN was a big mover last session, as the company saw its shares rise over 48% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $32.55 to $35.55 in the past one-month time frame.

The stock gained after issuing the positive results from its phase II trial testing of its idiopathic pulmonary fibrosis therapy.

The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter has moved lower over the same time period. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

FibroGen currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.

FibroGen, Inc Price

FibroGen, Inc Price | FibroGen, Inc Quote

A better-ranked stock in the Medical – Drugs industry is Alpine Immune Sciences, Inc. ALPN, which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FGEN going up? Or down? Predict to see what others think: Up or Down

More Stock News: Tech Opportunity Worth $386 Billion in 2017

From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.

Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.